Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review

Abstract

Background and Objectives: The incidence of distant metastases in patients with head and neck cancer (HNC) is approximately 10%. Pulmonary metastases are the most frequent distant location, with an incidence of 70–85%. The standard treatment options are chemo-, immuno- and radiotherapy. Despite a benefit for long-term survival for patients with isolated pulmonary metastases, pulmonary metastasectomy (PM) is not the treatment of choice. Furthermore, many otorhinolaryngologists are not sufficiently familiar with the concept of PM. This work reviews the recent studies of pulmonary metastatic HNC and the results after pulmonary metastasectomy. Materials and Methods: PubMed, Medline, Embase, and the Cochrane library were checked for the case series’ of patients undergoing metastasectomy with pulmonary metastases published since 1 January 2000. Results: We included the data of 15 studies of patients undergoing PM. The 5-year survival rates varied from 21% to 59%, with median survival from 10 to 77 months after PM. We could not identify one specific prognostic factor for long-term survival after surgery. However, at least most studies stated that PM should be planned if a complete (R0) resection is possible. Conclusions: PM showed reliable results and is supposedly the treatment of choice for patients with isolated pulmonary metastases. Patients not suitable for surgery may benefit from other non-surgical therapy. Every HNC patient with pulmonary metastases should be discussed in the multidisciplinary tumor board to optimize the therapy and the outcome.

Radiomics in Lung Metastases: A Systematic Review

“…Treatment options for LM may include local therapies, such as thermal ablation techniques and stereotactic ablative body radiation [ 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 ], chemotherapy [ 97 , 98 ] and, in selected cases, surgery [ 99 , 100 , 101 ]. The introduction of new systemic treatments, including immunotherapy and target therapies, has improved the prognosis of patients with metastatic tumors, but only a subset of mutated patients can benefit from such treatments [ 102 ].…”

Lungenmetastasen – Onkologische Bedeutung und Therapie

“…Adenoidzystische Karzinome haben dabei eine bessere Prognose im Vergleich zu Plattenepithelkarzinomen [ 16 ]. Ein hohes Patient:innenalter und Lokalrezidive vor Auftreten von Lungenmetastasen sind Faktoren, die mit einer schlechteren Prognose und einem schlechteren Gesamtüberleben einhergehen [ 17 , 18 ].…”

ALDH1: A potential therapeutic target for cancer stem cells in solid tumors

“…Head and neck carcinomas (HNCs) are the sixth most common cancer worldwide ( 178 ), which are characterized by the unregulated growth of tumor cells in various parts of the head and neck, such as the buccal mucosa, floor of the mouth, tongue, oropharynx, hypopharynx, esophagus, nasopharynx, and salivary glands ( 179 ), and more than 90% of HNCs are squamous cell carcinomas (HNSCC) ( 180 ). HNCs have poor survival, and poor prognosis ( 181 ), and CSCs have been attributed to poor treatment outcomes and survival in HNSCC ( 13 ).…”